Keywords: Celgene, Revlimid, Ph III failure, Castrate-resistant prostate cancer
Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure
Article | 23 November 2011
There was disappointment for blockbuster for multiple myeloma drug Revlimid (lenalidomide) when the Swiss subsidiary of US biotech firm Celgene ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
